Newhall Charles W III's Form 4 filing
Supernus Pharmaceuticals, Inc. (SUPN) · filed Nov 20, 2023
- Accession no.
- 0001104659-23-119962
- Filed
- Nov 20, 2023
- Trade date
- Nov 16, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $70.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Newhall Charles W IIICIK 0001005544 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 16, 2023 | Common Stock | MOption exerciseAcquired | +7,457 | $9.24 | +$68,902.68 | 119,589 | Direct | |
| Nov 16, 2023 | Common Stock | SSaleDisposed | −2,500 | $28.01 | −$70,025 | 117,089 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 16, 2023 | Common Stock | MOption exerciseDisposed | −7,457 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.